Gilead Sciences, Inc. (GILD)
136.05
+4.91
(+3.74%)
USD |
NASDAQ |
Jan 23, 13:46
Gilead Sciences Cash from Investing (Quarterly): -427.00M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen, Inc. | -414.00M |
| Johnson & Johnson | -- |
| Eli Lilly & Co. | -2.983B |
| Merck & Co., Inc. | -283.00M |
| Regeneron Pharmaceuticals, Inc. | -402.90M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 4.108B |
| Cash from Financing (Quarterly) | -1.489B |
| Free Cash Flow | 9.162B |
| Free Cash Flow Per Share (Quarterly) | 3.159 |
| Free Cash Flow to Equity (Quarterly) | 3.966B |
| Free Cash Flow to Firm (Quarterly) | 4.176B |
| Free Cash Flow Yield | 5.36% |